Table 2 Antibody status for Helicobacter pylori infection, CagA antibody status and the risk of Barrett’s oesophagus
Helicobacter pylori antibody statusCagA+ antibody statusNumber of subjectsOR* (95% CI)OR* (95% CI)
Barrett’s oesophagus/GORD/controlsBarrett’s oesophagus vs controlsBarrett’s oesophagus vs GORD patients
NegativeNegative263/259/2251.001.00
Positive10/13/31.95 (0.48 to 7.83)0.78 (0.30 to 2.00)
PositiveNegative31/19/440.61 (0.35 to 1.04)1.66 (0.89 to 3.13)
Positive5/10/230.08 (0.02 to 0.35)0.30 (0.06 to 1.45)
All H pylori-positive subjects†36/29/670.42 (0.26 to 0.70)1.24 (0.71 to 2.18)
  • *Adjusted for gender, age, home facility location, body mass index, ethnicity, smoking status, educational status and multivitamin use. †These include both CagA-positive and CagA-negative subjects.

  • CagA, cytotoxin-associated gene product A; GORD, gastro-oesophageal reflux disease.